Sgx Pharmaceuticals, Inc.

Attenuon, LLC

Selexagen Therapeutics, Inc.

Stephanie Hopkins

Ruo W Steensma

Stefan N Gradl

Chixu Chen

Mark E Wilson

William D Arnold

Andreas Gosberg

Brian Walter Eastman

Paul A Sprengeler

Ian A McDonald

Zhe Li

Pierre Bounaud

Gavin C Hirst

Masaki Tomimoto

Jean-Michel Andre Vernier

Anthony B Pinkerton

Robert J Ternansky

William Charles Ripka

Graham Parry

Johnny Uy

Andrew P Mazar

Won Hyung Yoon

Patricia L Gladstone

Pierre-Yves Bounaud

Amy Lynn Allan

Richard Pracitto

Patrick O'Connor

Fernando Donate

John May

Sean M O'Hare

Paul E Sprengeler

Khanh Thi Tuong Nguyen

Jeffrey M Blaney

Marian Plunkett

Described herein are compounds, pharmaceutical compositions and methods for the inhibition of Hedgehog signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human and veterinary disease and disorders.

Hedgehog inhibitors

The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.

Fused ring heterocycle kinase modulators

The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.

Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway disease, autoimmune diseases, metabolic disease, infection, CNS disease, brain tumor, obesity, asthma, hematological disorder, degenerative neural disease, cardiovascular disease, or disease associated with angiogenesis, neovascularization, or vasculogenesis.

Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators

The present invention provides novel pyrimidinyl-thiophene kinase modulators and methods of using the novel pyrimidinyl-thiophene kinase modulators to treat diseases mediated by kinase activity.

Pyrimidinyl-thiophene kinase modulators

The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.

Pyrrolo-pyridine kinase modulators

The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, pharmaceutical compositions of these peptides and methods of using these peptides and pharmaceutical compositions of these peptides to treat diseases associated with aberrant vascularization.

Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

Growing community of inventors

Poway, CA, United States of America

Stephanie Hopkins